from the transfer of H3N8 equine influenza virus to dogs; and the H3N2 CIV, which is an 27 avian-origin virus that adapted to infect dogs. Influenza infections are most effectively 28 prevented through vaccination to reduce transmission and future infection. Currently, 29 only inactivated influenza vaccines (IIVs) are available for the prevention of CIV in dogs. 30
However, the efficacy of IIVs is suboptimal and novel approaches are necessary for the 31 prevention of disease caused by this canine respiratory pathogen. Using reverse 32 genetics techniques, we have developed a live-attenuated CIV vaccine (LACIV) for the 33 prevention of H3N8 CIV. The H3N8 LACIV replicates efficiently in canine cells at 33 o C 34 but is impaired at 37-39 o C temperatures, and was attenuated when compared to wild-35 type H3N8 CIV, in vivo and ex vivo. The LACIV was able to induce protection against 36 H3N8 CIV challenge with a single intranasal inoculation in mice. Immunogenicity and 37 protection efficacy were better than that observed with a commercial CIV H3N8 IIV, but 38 provided limited cross-reactive immunity and heterologous protection against H3N2 CIV. 39
These results demonstrate the feasibility of implementing a LAIV approach for the 40 prevention and control of H3N8 CIV in dogs and suggest the need for a new LAIV for 41 the control of H3N2 CIV. In order to develop a LAIV for the treatment of CIV H3N8 infections, we introduced 133 the ts, ca, att mutations identified in the A/AA/6/60 LAIV into CIV H3N8 (referred to 134 henceforth as LACIV H3N8) using reverse genetics (39 antibodies: TCRβ-PerCPCy5.5, CD8α-FITC, CD4-BV421, CD44-APCCy7, and CD62L-267 PECy7. Cells were subsequently stained for viability using Live Dead Aqua (Invitrogen). 268
All antibodies were obtained from eBioscience, BD Biosciences, or Biolegend. PA and 269 NP tetramers were obtained from the NIH tetramer core facility (Atlanta, GA). Cells 270 were analyzed by an LSRII (BD Biosciences) in the University of Rochester Flow 271
Cytometry core facility and analyzed using FlowJo software (Tree Star). 272
ELISAs 273
ELISAs were performed as previously described (40) 
HAI assays 284
To evaluate the presence of H3N8 CIV neutralizing antibodies, mice sera were 285 treated with receptor-destroying enzyme (RDE; Denka Seiken) and heat inactivated for 286 30 min at 56°C. Sera were then serially 2-fold diluted (starting dilution of 1:50) in 96-well 287 V-bottom plates and mixed 1:1 with 4 hemagglutinating units (HAU) of WT H3N8 CIV for 288 30 min at room temperature. The HAI titers were determined by adding 0.5% turkey red 289 blood cells (RBCs) to the virus-antibody mixtures for 30 min on ice, as previously 290 described (40). The GMT and SDs from individual mice (N= 6) were calculated from the 291 last well where hemagglutination was inhibited. 292
Canine tracheal explants preparation and virus titrations 293
Three dog tracheas were harvested from healthy Beagles (Charles River 294 Laboratories) that had been used as negative controls in unrelated studies. Briefly, 295 tracheas were collected aseptically immediately upon euthanasia and transported in 296 pre-warmed medium as previously described (18). Tracheas were washed 5 times for a 297 total period of 4h and maintained at 33°C, 5% CO 2 , and 95% humidity between washes. for a total of 6 days at 33°C, 5% CO 2 , and 95% humidity. 302
Tracheal explants were infected after a period of 24 h post-preparation (designed as 303 day zero) with 200 PFU of WT or LACIV H3N8, or mock infected with culture medium. 304
Inoculated explants were sampled for virus quantification, bead clearance assays, and 305 histology at days 0, 1, 3 and 5 p.i. Viral replication was evaluated by plaque assays on 306
MDCK cells. 307

Estimation of bead clearance time 308
The ciliary function of tracheal explants was evaluated as previously described (18), 309
by placing five microliters of polystyrene microsphere beads (Polysciences, 310
Northampton, UK) on the explants apical surface and measuring the time to displace 311 the beads. 312
Histological analysis and immunohistochemistry 313
After collection, the explants were fixed in 10% buffered formalin for a minimum of 314 48 h, before paraffin embedding and sectioning. Subsequently, 4 μm sections of paraffin 315 embedded tissue were either stained with haematoxylin and eosin (H&E) for 316 histopathological evaluation or immunostained for the viral NP using standard 317 
Generation and characterization of H3N8 LACIV 344
We introduced four ts mutations identified in previous studies into the PB2 and PB1 345 genes of H3N8 CIV (34, 47) (Fig. 1) . No mutation was introduced into the viral NP since 346 H3N8 CIV NP already contains a G at position 34. 347
To determine whether the mutations introduced into the PB2 and PB1 genes confer 348 a ts phenotype to the H3N8 CIV polymerase, we performed a minigenome assay. Both, 349
WT and LACIV H3N8 resulted in similar Gluc expression levels at 33ºC (Fig. 1B) , but 350
Gluc expression was reduced at higher temperatures (37ºC and 39ºC) in cells 351
transfected with the H3N8 LACIV plasmids. This shows that those mutations resulted in 352 a ts phenotype when introduced in the H3N8 CIV, as previously described for A/AA/6/60 353
H2N2 and other influenza viruses (36-38). 354
We next generated an H3N8 LACIV using plasmid-based reverse genetic 355 approaches (40, 48) and evaluated the viral replication kinetics in MDCK cells infected 356 at low (0.001) MOI, and compared to the WT H3N8 CIV (Fig. 2) . At 33ºC, both WT and 357 LACIV H3N8 grew with the same kinetics and reached similar high titers (10 7 FFU/ml) at 358 48-72 h p.i. (Fig. 2A) . At higher temperatures (37ºC and 39ºC) the WT H3N8 CIV 359 replicated at similar levels as those observed at 33ºC while H3N8 LACIV titers were 360 reduced ~2-3-logs at 37ºC (Fig. 2B) or was not detected at 39ºC (Fig. 2C) . These 361 results demonstrate that mutations introduced in PB2 and PB1 conferred a ts phenotype 362 to H3N8 CIV. 363
LACIV H3N8 is attenuated in vivo in mice 364
on November 23, 2017 by guest http://jvi.asm.org/
Downloaded from
As the H3N8 LACIV presented defects in replication at higher (37ºC and 39ºC) 365 temperatures, we next investigated whether H3N8 LACIV was also attenuated in mice. No 366 signs of infection were detected after infection with WT H3N8 CIV. Therefore, CIV titers in the 367 lungs of infected (10 5 PFU) mice were determined on days 2 (N=3) and 4 (N=3) p.i. and used 368 as a measure of viral attenuation (Fig. 3) . Notably, virus titers in the lungs were only detected 369 in mice inoculated with WT H3N8 CIV and no virus was detected in mice infected with the 370 H3N8 LACIV. These results indicate that H3N8 LACIV is also attenuated in vivo. 371
Intranasal vaccination with H3N8 LACIV induces protective immunity against 372
WT H3N8 CIV challenge 373
To evaluate the immunity generated by the H3N8 LACIV, mice (N=6) were 374 vaccinated (i.n.) with 10 3 PFU of H3N8 WT or LACIV, mock vaccinated with PBS, or 375 vaccinated (i.m.) with 100 µl of Nobivac, a commercial IIV against H3N8 CIV (Fig. 4) . 376
Humoral immune responses were evaluated in mice sera collected 2 weeks later (Fig.  377   4A) . Total H3N8 CIV antibody responses were characterized by ELISA using cell 378 lysates from mock-or H3N8 CIV-infected MDCK cells (48). Mice vaccinated with the 379 H3N8 LACIV elicited high serum IgG titers against parental H3N8 CIV, while antibody 380 titers of mice vaccinated with Nobivac were lower than those in the H3N8 LACIV or WT 381 vaccinated mice (Fig. 4A) . Additionally, HAI assays were performed to examine the 382 presence of anti-HA neutralizing antibodies on sera from vaccinated mice (Fig. 4B) , 383 showing that HAI titers against CIV H3N8 were higher in mice vaccinated with the H3N8 384 LACIV than those observed in mice vaccinated with the H3N8 IIV. 385
To further examine the immunogenicity of LACIV, we evaluated if the virus can 386 induce a localized CD8 T cell response (Fig. 5) . To this end, mice (N=4) were 387 on November 23, 2017 by guest http://jvi.asm.org/ Downloaded from immunized as described above and ten days p.i., lungs and spleen samples were 388 collected and single-cell preparations made for flow cytometric analysis (49). Live, CD8 389 T cells were further gated for a H3N8 CIV-specific population (49, 46). Results showed 390 that vaccination with H3N8 LACIV induced elevated levels of NP and PA-specific lung 391 CD8 T cells, similar to those induced by WT virus in both lungs (Fig. 5A ) and spleen 392 (Fig. 5B) . Importantly, animals vaccinated with Nobivac did not show a T cell response 393 either in the lung (Fig. 5A) or the spleen (Fig. 5B) , highlighting important differences in 394 induced immunity between H3N8 LACIV and the H3N8 IIV. 395
We next evaluated the ability of H3N8 LACIV to induce protective immunity. Mice 396 (N=6) were vaccinated i.n. with 10 3 PFU of H3N8 WT or LACIV, i.m. with 100 µl of the 397 IIV Nobivac, or mock vaccinated with PBS. Two weeks later mice were challenged with 398 10 5 PFU of WT H3N8 CIV and viral titers in the lungs of infected mice (N=3/group) were 399 determined 2 and 4 days after challenge (Fig. 6) . Mock-vaccinated mice showed high 400 viral titers in the lungs at days 2 and 4 p.i., while mice immunized with H3N8 WT CIV 401 and with LACIV showed no detectable virus in the lungs at those times (Fig. 6) . Mice 402 vaccinated with the H3N8 IIV showed high viral titers at day 2, but no detectable virus at 403 day 4 p.i. (Fig. 6) . 404
H3N8 LACIV is attenuated in canine tracheal explants as compared to H3N8 405
WT CIV 406
To compare LACIV and WT H3N8 CIV pathogenicity and replication efficiency at the 407 site of infection within dogs (Fig. 7) , we inoculated dog tracheal explants with each virus 408 and compared histological lesions (Fig. 7A) , viral NP expression (Fig. 7B) , changes in 409 ciliary function (Fig. 7C ) and viral replication (Fig. 7D) with thinning and desquamation of the epithelium, loss of cilia (Fig 5A) , and significant 412 reduction of ciliary function (Fig. 7C) between days 1 and 5 p.i. Histological damages 413 induced by H3N8 LACIV were delayed and reduced compared to WT H3N8 CIV, as the 414 epithelium maintained its normal thickness until day 3 p.i. (Fig. 7A) and the ciliary 415 function (Fig. 7C) was only significantly reduced from day 3 p.i. Viral kinetics (Fig. 7D)  416 and NP expression (Fig. 7B) were comparable between the two viruses, although only 417 WT H3N8 CIV was detectable at day 1 p.i. (Fig. 7D) . Overall, these results indicate that 418 H3N8 LACIV pathogenicity is attenuated in canine tracheal explants compared to its WT 419 counterpart. 420
H3N8 LACIV provides limited protection against heterologous H3N2 CIV 421 challenge 422
We next evaluated if H3N8 LACIV could induce protective immunity against a 423 heterologous H3N2 CIV challenge (Fig. 8) . Mice (N=6) were vaccinated (i.n.) with 10 CIV were evaluated by ELISA using cell lysates from mock-or H3N2 CIV-infected 427 MDCK cells as antigens (Fig. 8A) . In addition, antibodies against the HA (Fig. 8B) or 428 NA (Fig. 8C) proteins of H3N2 CIV were also evaluated. When the cell lysate was used 429 as antigen, antibodies against H3N2 CIV were detected in sera of mice vaccinated with 430 WT H3N8 CIV and, to a lower extent, in mice vaccinated with H3N8 LACIV, although 431 the levels were lower than those against H3N8 CIV (Fig. 8A) . Similarly, using the 432 (Fig. 8B) . However no antibodies were detected against the NA protein (Fig. 8C) . 435 No detectable IgG antibodies against H3N2 CIV were detected in mice vaccinated with 436 the H3N8 IIV Nobivac either using the cell extracts (Fig. 8A) or the recombinant 437 proteins (Figs. 8B and C) . The H3N2 CIV IIV induced higher IgG antibodies against 438 H3N2 CIV in all cases, as expected (Figs. 8A-8C) . 439
The lower level of cross-reactive immunity against H3N2 CIV upon vaccination with 440 the H3N8 LACIV was confirmed after challenge (i.n.) with H3N2 CIV 2 weeks post-441 vaccination (Fig. 8D) . Mock-vaccinated mice showed high H3N2 CIV titers that were 442 undistinguishable from those seen in animals vaccinated with the H3N8 CIV IIV Nobivac. Here we report a novel LAIV prepared using plasmid-based reverse genetics 458 techniques, which may be used for the prevention of H3N8 CIV. We have generated a 459 recombinant H3N8 CIV containing the mutations responsible for the ts phenotype of the 460 human A/AA/6/60 H2N2 LAIV, resulting in ts H3N8 CIV (LACIV) that was highly 461 attenuated in vivo and ex vivo when compared to its WT counterpart. Our H3N8 LACIV 462 was able to confer, upon a single i.n. immunization in mice, complete protection against 463 challenge with WT H3N8 CIV. This demonstrates the feasibility of using the ts H3N8 464 LACIV as a safe, immunogenic and protective vaccine to control H3N8 CIV in dogs. replication and pathogenesis were also restricted in canine tracheal explants, and we 503 are currently evaluating the safety, immunogenicity and protection efficacy of our H3N8 504 LACIV in dogs, the real target population. 505
To achieve protection in dogs, animals are vaccinated (i.m.) with 1 ml of the CIV 506 H3N8 IIV (Nobivac) using a two-dose regime (68). The average weight of a male or 507 female mouse is ~ 20 gr while the average weight of a female or male beagle dog is ~ 508 10 kg. Thus, in principle mice should be vaccinated with 500 times less (just 2 µl) of the 509 CIV H3N8 IIV than dogs. However, in our experiments, mice were immunized (i.m.) with 510 100 µl of the CIV H3N8 IIV -a 50X higher dose than on a weight basis. In addition, to 511 evaluate the amount of antigen in the CIV H3N8 IIV, we performed an hemagglutination 512 assay (HA) using the commercial CIV H3N8 IIV or our CIV H3N8 LAIV. The assay 513
showed that mice vaccinated with the CIV H3N8 IIV were inoculated with approximately 514 and in vitro (dog tracheal explants), but were able to confer complete protection against 526 challenge with WT CIV H3N8 (28). Moreover, the immunogenicity and protection 527 efficacy of our NS1 mutant H3N8 CIVs was also better than that observed with an H3N8 528 CIV IIV (28). Future research should determine which one of these attenuation 529 strategies (NS1 mutant or ts H3N8 CIVs) is more efficient for their implementation as a 530 LAIV for the prevention and control of H3N8 CIV in dogs. 
